Hungary’s Egis Picks Up Skin-Care Portfolio From Teva

 
• By Tom Gallen

Egis is the beneficiary as Teva again trims its OTC portfolio with the sale of Hungarian skin-care brand Neogranormon.

(Shutterstock)

More from Deals

More from Strategy